Switch theme
Sign up to access all valuation multiples
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
2017
164
Last FY Revenue n/a
LTM EBITDA -$156M
-$13.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cabaletta Bio has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$156M.
In the most recent fiscal year, Cabaletta Bio achieved revenue of n/a and an EBITDA of -$113M.
Cabaletta Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cabaletta Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$156M | XXX | -$113M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$154M | XXX | -$125M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$148M | XXX | -$116M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Cabaletta Bio's stock price is $2.
Cabaletta Bio has current market cap of $156M, and EV of -$13.4M.
See Cabaletta Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$13.4M | $156M | XXX | XXX | XXX | XXX | $-2.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Cabaletta Bio has market cap of $156M and EV of -$13.4M.
Cabaletta Bio's trades at n/a EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Cabaletta Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cabaletta Bio has a P/E ratio of -1.1x.
See valuation multiples for Cabaletta Bio and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $156M | XXX | $156M | XXX | XXX | XXX |
| EV (current) | -$13.4M | XXX | -$13.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCabaletta Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
Cabaletta Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cabaletta Bio's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cabaletta Bio and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 55% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cabaletta Bio acquired XXX companies to date.
Last acquisition by Cabaletta Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Cabaletta Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Cabaletta Bio founded? | Cabaletta Bio was founded in 2017. |
| Where is Cabaletta Bio headquartered? | Cabaletta Bio is headquartered in United States of America. |
| How many employees does Cabaletta Bio have? | As of today, Cabaletta Bio has 164 employees. |
| Who is the CEO of Cabaletta Bio? | Cabaletta Bio's CEO is Dr. Steven Nichtberger,M.D.. |
| Is Cabaletta Bio publicy listed? | Yes, Cabaletta Bio is a public company listed on NAS. |
| What is the stock symbol of Cabaletta Bio? | Cabaletta Bio trades under CABA ticker. |
| When did Cabaletta Bio go public? | Cabaletta Bio went public in 2019. |
| Who are competitors of Cabaletta Bio? | Similar companies to Cabaletta Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Cabaletta Bio? | Cabaletta Bio's current market cap is $156M |
| Is Cabaletta Bio profitable? | Yes, Cabaletta Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cabaletta Bio? | Cabaletta Bio's last 12 months EBITDA is -$156M. |
| What is the current EV/EBITDA multiple of Cabaletta Bio? | Current EBITDA multiple of Cabaletta Bio is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
